MiMedx Group (MDXG) TD Cowen 45th Annual Healthcare Conference summary

Company overview and market position

• Focuses on advanced wound care, leveraging placental tissue and proprietary processes for chronic and surgical applications.

• Operates two manufacturing facilities, with 900 employees, and sources tissue from 50+ birthing centers.

• Holds a strong IP portfolio and is recognized as a pioneer in placental tissue processing.

• 90%+ of business is domestic, with growing international presence, notably in Japan.

• Combines direct sales force and agent network for broad market coverage.

Product portfolio and innovation

• Main products include EPIFIX (wound care), AMNIOEFFECT (surgical), and HELIOGEN (bovine collagen xenograft).

• Over 3 million allografts manufactured; EPIFIX is widely covered by commercial payers.

• AMNIOEFFECT has seen strong uptake since launch; HELIOGEN is the first 510(k) cleared xenograft.

• MiMedx Connect portal enhances customer engagement and streamlines ordering and insurance processes.

• Ongoing expansion into surgical applications, supported by a growing evidence base.

Financial performance and strategic priorities

• Achieved 9% revenue growth in 2024, with 20%+ EBITDA margins and over $100M in gross cash.

• Wound segment accounts for two-thirds of revenue, surgical for one-third; wound grew 12%, surgical 8% (excluding transitory items).

• Leadership team has transformed the company into a nimble, focused industry leader over the past two years.

• Strategic focus on innovation, expanding surgical footprint, and customer intimacy.

• Strong balance sheet provides flexibility for organic and inorganic growth.